Product Details
| Product Name:
Tidutamab |
CAS No.:
2148354-90-7 |
| Purity:
97.9% (SDS-PAGE); 97.8% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2025/07/28 |
Product Introduction
Bioactivity
| Name | Tidutamab |
| Description | Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors. |
| In vitro | Tidutamab was able to bind to human SSTR2+ CHO cells in the concentration range of 0-100,000 ng/mL with an ED50 value of 2.2 μg/mL and mediated the killing of SSTR2+ target cells by T cells. [1] |
| In vivo | In NSG mice, Tidutamab was able to stimulate killing of SSTR2+ A549 lung cancer tumors by human T cells after a single intraperitoneal injection at a dose of 3 mg/kg. [1] |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | CD3 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:2762617-31-0
$84.00 / 1mg
-
CAS:478-01-3
$52.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States